SCHEMBL1952771

SCHEMBL1952771

CC1(C)NC(=O)C2(CCN(C(=O)/C=C/c3ccccc3C(F)(F)F)CC2)c2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GPR183 P32249 1/20 0.46
▸ NFKB1 P19838 1/20 0.45
▸ MAOB P27338 7/20 0.38
▸ P4HB P07237 1/20 0.38
▸ ABCG2 Q9UNQ0 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ KEAP1 Q14145 2/20 0.37
▸ NFE2L2 Q16236 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ ITGAL P20701 2/20 0.37
▸ ITGB2 P05107 1/20 0.37
▸ ICAM1 P05362 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MAOA P21397 1/20 0.36
▸ BACE1 P56817 1/20 0.36
▸ PTPN11 Q06124 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1952772 1.00 GPR183 (0.46) GPR183NFKB1MAOBP4HBABCG2
SCHEMBL12569867 0.81 GPR183 (0.45) GPR183NFKB1MAOBP4HBABCG2
SCHEMBL12569927 0.80 GPR183 (0.44) GPR183NFKB1MAOBP4HBABCG2
SCHEMBL1951702 0.79 GPR183 (0.47) GPR183NFKB1MAOBP4HBABCG2
SCHEMBL1951705 0.79 GPR183 (0.47) GPR183NFKB1MAOBP4HBABCG2
SCHEMBL1952829 0.79 GPR183 (0.45) GPR183NFKB1MAOBP4HBABCG2
SCHEMBL1952831 0.79 GPR183 (0.45) GPR183NFKB1MAOBP4HBABCG2
SCHEMBL12569871 0.78 GPR183 (0.46) GPR183NFKB1MAOBP4HBABCG2
SCHEMBL13689925 0.78 IP6K1 (0.45) GPR183NFKB1MAOBP4HBABCG2
SCHEMBL12569942 0.78 GPR183 (0.42) GPR183NFKB1MAOBP4HBABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265588-B1 INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1 VITAE PHARMACEUTICALS INC (US) 2013-06-26 — — EP disclosed
US-8383629-B2 Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 VITAE PHARMACEUTICALS, INC. (US) 2013-02-26 — — US disclosed
US-8383629-B2 Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 VITAE PHARMACEUTICALS, INC. (US) 2013-02-26 — — US disclosed
US-8383629-B2 Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 VITAE PHARMACEUTICALS, INC. (US) 2013-02-26 — — US disclosed
US-20110136821-A1 Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 VITAE PHARMACEUTICALS INC. 2011-06-09 — — US disclosed
US-20110136821-A1 Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 VITAE PHARMACEUTICALS INC. 2011-06-09 — — US disclosed
US-20110136821-A1 Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 VITAE PHARMACEUTICALS INC. 2011-06-09 — — US disclosed
WO-2009108332-A1 INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 VITAE PHARMACEUTICALS, INC. (US) 2009-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136821-A1 Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 HSD11B1, HSD17B1, HSD3B1 GPR183 1523/4885NFKB1 1003/4885MAOB 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback